Clinical Research & Clinical Trial Management | Project Owner

1. A rapidly growing multi-billion-dollar market Clinical research represents a major and growing sector of the life sciences industry. According to Grand View Research, the global Clinical Trials Market was valued at USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033 , representing a compound annual growth rate (CAGR) of 7.7% . Within this broader ecosystem, the global eClinical Solutions Market was estimated at USD 11.5 billion in 2025 and is expected to grow even faster, reaching USD 35.1 billion by 2033 with a projected CAGR of 15.1% . References Market (USD) 2025 2026 (Estimate) 2033 Forecast CAGR (2026–2033) Source Clinical Trials Market $89.0 B $94.0 B $158.4 B 7.7% Grand View Research eClinical Solutions Market $11.5 B $13.1 B $35.1 B 15.1% Grand View Research The comparison highlights an important trend. While the clinical trials industry ...

 FDA Form 483 is frequently mentioned in discussions about FDA inspections, Good Clinical Practice (GCP), and pharmaceutical quality systems. While the document itself is well known within regulatory affairs and quality assurance, a large amount of publicly available information surrounding Form 483 is often overlooked. This short overview collects several useful FDA and industry resources that may help readers better understand inspection observations, public databases, current regulatory developments, and examples of completed inspection forms. One of the most useful starting points is the FDA Office of Inspections and Investigations (OII) Electronic Reading Room. The database contains publicly released inspection-related documents obtained through the Freedom of Information Act (FOIA), including Form 483 inspection observations, Establishment Inspection Reports (EIRs), warning letters, and other inspection records. It provides an opportunity to explore how FDA inspections are ...

Quality by Design (QbD) and Risk-Based Monitoring (RBM) are frequently discussed in modern clinical research. Rather than attempting to eliminate every minor error, the emphasis has shifted toward protecting participant safety and ensuring the reliability of critical data through a risk-based approach. A recent discussion published by RAPS following the DIA Global Annual Meeting explored these principles in the context of FDA inspections and Form 483 observations. One example used during the discussion was particularly memorable. A clinical trial was compared to a field of corn. Each patient represented a stalk, each data point a kernel, and the CRA was expected to inspect every kernel on every cob in every row of the field. The message was that expecting a CRA to examine everything is unrealistic, and criticizing them for missing only a few "kernels" among billions is equally unreasonable. ( https://www.raps.org/resource/fda-investigator-experts-seek-to-dispel-misperceptio...